HK1054697A1 - Pharmaceutical preparations - Google Patents

Pharmaceutical preparations

Info

Publication number
HK1054697A1
HK1054697A1 HK03107084A HK03107084A HK1054697A1 HK 1054697 A1 HK1054697 A1 HK 1054697A1 HK 03107084 A HK03107084 A HK 03107084A HK 03107084 A HK03107084 A HK 03107084A HK 1054697 A1 HK1054697 A1 HK 1054697A1
Authority
HK
Hong Kong
Prior art keywords
formulations
release
relates
fusion
pharmaceutical formulations
Prior art date
Application number
HK03107084A
Other languages
English (en)
Inventor
Torsten Hoffmann
Michael Pieroth
Gerhard Zessin
Original Assignee
Awd Pharma Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26004678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1054697(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE2000110509 external-priority patent/DE10010509A1/de
Application filed by Awd Pharma Gmbh & Co Kg filed Critical Awd Pharma Gmbh & Co Kg
Publication of HK1054697A1 publication Critical patent/HK1054697A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
HK03107084A 2000-03-08 2003-09-30 Pharmaceutical preparations HK1054697A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2000110509 DE10010509A1 (de) 2000-03-08 2000-03-08 Pharmazeutische Formulierungen
US18796200P 2000-03-09 2000-03-09
PCT/EP2001/002500 WO2001066081A2 (de) 2000-03-08 2001-03-06 Pharmazeutische formulierungen enthaltend saccharosefettsäureester zur steuerung der wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
HK1054697A1 true HK1054697A1 (en) 2003-12-12

Family

ID=26004678

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03107084A HK1054697A1 (en) 2000-03-08 2003-09-30 Pharmaceutical preparations

Country Status (23)

Country Link
EP (1) EP1267828B1 (ko)
JP (1) JP2003528829A (ko)
KR (1) KR20020083171A (ko)
CN (1) CN1212831C (ko)
AT (1) ATE334659T1 (ko)
AU (1) AU2001250365A1 (ko)
BG (1) BG107064A (ko)
BR (1) BR0109036A (ko)
CA (1) CA2339913C (ko)
CZ (1) CZ20023009A3 (ko)
DE (1) DE50110617D1 (ko)
EA (1) EA200200951A1 (ko)
EE (1) EE200200504A (ko)
GE (1) GEP20053455B (ko)
HK (1) HK1054697A1 (ko)
HR (1) HRP20020804B1 (ko)
HU (1) HUP0204513A3 (ko)
IS (1) IS6511A (ko)
NO (1) NO20024237D0 (ko)
NZ (1) NZ521215A (ko)
PL (1) PL202935B1 (ko)
SK (1) SK13252002A3 (ko)
WO (1) WO2001066081A2 (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074029A1 (en) * 2002-03-07 2003-09-12 Vectura Limited Fast melt multiparticulate formulations for oral delivery
KR100712356B1 (ko) * 2003-01-23 2007-05-02 (주)아모레퍼시픽 서방성 제제 및 그의 제조방법
DE10341264A1 (de) * 2003-09-04 2005-03-24 Grünenthal GmbH Schmelzformulierte, multipartikuläre orale Darreichungsform
BRPI0506807A (pt) * 2004-04-22 2007-05-29 Mor Research Applic Ltd método de gerenciamento de consumo de alimento e composição farmacológica
KR20110052641A (ko) * 2008-07-18 2011-05-18 베일언트 파마슈티컬스 인터내셔널 변형 방출형 제형 및 이의 이용 방법
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
DE102009013611A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Festes Retigabin in nicht-kristalliner Form
DE102009013612A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
DE102009013613A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
MX2012008475A (es) * 2010-01-20 2013-11-01 Valeant Pharmaceuticals Int Formulacion de liberacion modificada y metodos para su uso.
WO2013004249A1 (en) 2011-07-05 2013-01-10 Concit Pharma Aps The use of serotonin receptor agonists for treatment of movement disorders
ES2616887T3 (es) * 2013-10-29 2017-06-14 Echo Pharmaceuticals B.V. Comprimido que contiene delta 9-tetrahidrocannabinol, método para su producción y uso de tal comprimido en el tratamiento oral
EP3541393A4 (en) * 2016-11-18 2020-06-17 The University Of Western Australia TASTE MASKING PRODUCT
CN107441055A (zh) * 2017-08-03 2017-12-08 山东则正医药技术有限公司 一种控释药物的制备方法
CN108853044B (zh) * 2018-07-06 2020-11-06 郑州明泽医药科技有限公司 一种硝苯地平缓释片及其制备方法
CN109679147B (zh) * 2018-12-28 2021-05-11 广西科技师范学院 植物微细纤维蔗糖脂肪酸酯富集物及制备方法
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
WO2021145625A1 (ko) * 2020-01-13 2021-07-22 한국유나이티드제약 주식회사 R-치옥트산 또는 이의 약학적으로 허용되는 염 및 장용코팅기제를 포함하는 약학조성물
CN111513192A (zh) * 2020-05-19 2020-08-11 北京中联华康科技有限公司 一种酯化半胱胺盐酸盐稳定型粉末及其制备方法与应用
CN114983964B (zh) * 2022-06-24 2024-05-03 广东恒健制药有限公司 一种头孢地尼颗粒剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63101320A (ja) * 1986-10-17 1988-05-06 Dainippon Pharmaceut Co Ltd バルプロ酸カルシウム製剤
JPH07267850A (ja) * 1994-03-28 1995-10-17 Eisai Co Ltd 不快味を防止した医薬組成物及びその製造方法
JP4078567B2 (ja) * 1997-04-25 2008-04-23 東和薬品株式会社 徐放性マイクロカプセル及びその製法
JP4299384B2 (ja) * 1997-07-15 2009-07-22 富山化学工業株式会社 溶出遅延防止細粒剤
TWI235068B (en) * 1998-03-26 2005-07-01 Fujisawa Pharmaceutical Co Sustained-release pharmaceutical composition
DE19840152A1 (de) * 1998-09-03 2000-03-09 Dresden Arzneimittel Calciumvalproat enthaltende pharmazeutische Zusammensetzungen mit retardierter Wirkstoff-Freisetzung, Verfahren zu deren Herstellung und deren Verwendung
DE19916383A1 (de) * 1999-03-31 2000-10-05 Schering Ag Pharmazeutische Zusammensetzung mit einem Extrusionsstoff

Also Published As

Publication number Publication date
IS6511A (is) 2002-08-20
EP1267828A2 (de) 2003-01-02
BR0109036A (pt) 2003-03-18
DE50110617D1 (de) 2006-09-14
HRP20020804A2 (en) 2004-12-31
NO20024237L (no) 2002-09-05
ATE334659T1 (de) 2006-08-15
CN1212831C (zh) 2005-08-03
CA2339913A1 (en) 2001-09-08
KR20020083171A (ko) 2002-11-01
JP2003528829A (ja) 2003-09-30
PL202935B1 (pl) 2009-08-31
PL362547A1 (en) 2004-11-02
CA2339913C (en) 2009-02-24
SK13252002A3 (sk) 2003-07-01
EE200200504A (et) 2004-02-16
EA200200951A1 (ru) 2003-02-27
WO2001066081A3 (de) 2002-03-14
HUP0204513A2 (en) 2003-05-28
GEP20053455B (en) 2005-02-25
NZ521215A (en) 2005-04-29
WO2001066081A2 (de) 2001-09-13
HRP20020804B1 (en) 2008-06-30
CN1418091A (zh) 2003-05-14
HUP0204513A3 (en) 2004-06-28
BG107064A (bg) 2003-04-30
EP1267828B1 (de) 2006-08-02
NO20024237D0 (no) 2002-09-05
CZ20023009A3 (cs) 2003-06-18
AU2001250365A1 (en) 2001-09-17

Similar Documents

Publication Publication Date Title
HK1054697A1 (en) Pharmaceutical preparations
IL158589A (en) Carboxylic acid substituted oxazole derivatives, process for their manufacture, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment and prophylaxis of diseases which are modulated by ppar-alpha and -gamma activators
TNSN01108A1 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
PT1311285E (pt) Composicao farmaceutica liquida contendo um derivado de eritropoietina
IL159843A0 (en) Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2001098290A3 (en) Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
IL145430A0 (en) N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
FR2743075B1 (fr) Procede de preparation de substances actives a partir de la nacre, produits obtenus, utiles notamment comme medicaments
MXPA02012889A (es) Esteres de acidos 4-alcoxi-ciclohexano-1-amino-carboxilicos y procedimiento para su obtencion.
WO2007078848A3 (en) Preparation of pharmaceutical salts of 3-o-(3',3'-dimethlsuccinyl) betulinic acid
WO2005065639A3 (en) Novel pharmaceutical compositions
NO20023551D0 (no) Ibuprofen-inneholdende aktivt middel-preparat
BR0311642A (pt) Formulação de divalproex de sódio de liberação aumentada
MXPA04003506A (es) Metodo para la preparacion de una composicion farmaceutica que comprende acido 5-aminosalicilico para el uso en el tratamiento de la colitis ulcerativa y de la enfermedad de crohn.
BG106952A (en) Controlled release pharmaceutical composition containing tramadol hydrochloride and method for its preparation
YU92103A (sh) Granulirani preparati gaboksadola
YU66902A (sh) Farmaceutski preparati koji sadrže estre masnih kiselina saharoze za kontrolisanje oslobađanja aktivnih sastojaka
CA2429793A1 (en) Interferon therapeutic effect enhancer
DE69927997D1 (de) Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
WO2002030391A3 (en) Method for determining the release of a peptide from a sustained release polylactide formulation
AU2001274138A1 (en) Propanolaminotetralines, preparation thereof and compositions containing same
BG106236A (en) Melt granulation

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE PRIORITY COUNTRY CODE FROM DE TO US

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100306